INTRODUCTION AND OBJECTIVES: Smooth muscle contraction in the hyperplastic prostate may drive urethral obstruction and subsequent lower urinary tract symptoms. Consequently, inhibition of contraction is an important strategy for medical therapy, but available options show insufficient efficacy. Development of novel options with higher efficacy requires adequate understanding of contractile mechanisms and identification of new targets. Recently, a possible role of polo-like kinase 1 (PLK1) has been suggested for smooth muscle contraction outside the lower urinary tract. Here, we examined effects of PLK1 inhibitors on contraction of human prostate tissue.
METHODS: Prostate tissues were obtained from radical prostatectomy (n¼122 patients). Smooth muscle contractions were studied in an organ bath, where they were induced by adrenergic and nonadrenergic agonists or electric field stimulation (EFS) after addition of solvent (control) or PLK inhibitor (SBE13, cyclapolin 9, TAK960, Ro-3280). RT-PCR, Western blot and immunofluorescence were performed for detection of PLK isoforms.
RESULTS: Noradrenaline and the a1-agonists phenylephrine and methoxamine (each 0.1-100 mM) induced concentration-dependent contractions of human prostate strips, which were significantly inhibited by SBE13 (1 mM) and cyclapolin 9 (3 mM). This inhibition was significant for different agonist concentrations, and between groups for nearly all agonist/inhibitor combinations (p<0.01, p<0.002, p<0.002 between SBE13 and control for noradrenaline, phenylephrine, methoxamine; p<0.002, p<0.02 for cyclapolin vs. control for noradrenaline, methoxamine). EFS induced frequence-dependent contractions, which were significantly inhibited by SBE13 (1 mM), cyclapolin 9 (3 mM), TAK960 (100 nM), and Ro-3280 (100 nM) (p<0.02 for SBE13 vs. control, p<0.03 for cyclapolin vs. control, p<0.006 for TAK960 vs. control, p<0.04 for Ro-3280 vs. control). Endothelin-1 (0.1-3 mM) and U46619 (0.1-30 mM) induced concentration-dependent contractions of prostate strips, which were not changed by SBE13 or cyclapolin 9. RT-PCR, Western blot, and immunofluorescence suggested expression of PLK1 in smooth muscle cells of the human prostate.
CONCLUSIONS: PLK inhibitors inhibit a1-adrenergic and neurogenic smooth muscle contractions in the prostate. A PLKdependent signalling pathway may confer divergent regulation of adrenergic and non-adrenergic contraction in the human prostate. + coexpressing mesenchymal stem cell population was previously identified in the stromal layer of the murine bladder which is altered after acute and partial outlet obstructions. We hypothesize that loss of Sca-1 + will inhibit the physiologic detrusor hypertrophy that occurs after obstruction leading to decreased compensatory function.
METHODS: 6-8 week-old male Sca-1 null mice and genetically unmodified (C57/BL6) mice both underwent surgical partial obstruction (PO) at the bladder neck. An additional cohort of Sca-1 null mice underwent sham surgery for comparison. Voiding stains on paper at 1, 2, and 4 weeks were analyzed for functional assessments of the bladder. Whole bladders were analyzed at 4 weeks by weight and distributed for histologic exam and RNA extraction. Bladder thickness and circumference were measured. Masson 0 s Trichome staining was used to calculate detrusor collagen to smooth muscle ratios and total smooth muscle content.
RESULTS: Comparisons were made between PO groups of Sca-1 null mice (Figure b ) and C57/BL6 mice (Figure c) , as well as between Sca-1 null mice who either underwent PO or sham surgery (Figure a) . PO led to increased bladder circumference in Sca-1 null mice (2.06AE0.42 cm) compared to the sham group (1.21AE0.25 cm) (p¼0.04). Mean bladder smooth muscle content in C57/BL6 mice was 0.83AE0.09 compared to 0.67AE0.10 in Sca-1 null mice (p¼0.02). Sca-1 null sham mice had a bladder smooth muscle composition of 0.88AE0.05 (p¼0.02). Lower collagen-to-smooth muscle ratios were also found in the C57/BL6 group at 0.23AE0.14 compared to 0.55AE0.25 in Sca-1 null mice (p¼0.03). Comparison graphs are shown in the Figure. CONCLUSIONS . 199, No. 4S, Supplement, Saturday, May 19, 2018 
